Skip to content
ETopical – Lifestyle
Home
Sample Page
Author:
Teva Pharmaceutical Industries Ltd
Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)
March 30, 2026
Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026
March 19, 2026
Teva Releases Q1 2026 Aide Memoire
March 19, 2026
←
Previous Page
1
2